NCT04264858 is a NA clinical trial of Immunoglobulin of cured patients in 2019-nCoV, sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.

What drugs are being tested in NCT04264858?

Interventions in NCT04264858: Immunoglobulin of cured patients, γ-Globulin.

What condition does NCT04264858 study?

NCT04264858 studies 2019-nCoV, Immunoglobulin of Cured Patients.

Is NCT04264858 still recruiting?

NCT04264858 is currently status unknown. Last updated 17 March 2020.

Last reviewed 2020-03-17 · How we verify

NCT04264858

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients

Status unknown NA Last updated 17 March 2020

What this trial tests

NA trial testing Immunoglobulin of cured patients in 2019-nCoV in 10 participants. Status unknown.

Timeline

17 March 2020

Primary endpoint
30 April 2020

31 May 2020

Quick facts

Lead sponsor	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	17 March 2020
Primary completion	30 April 2020
Estimated completion	31 May 2020
Sites	1 location across China

Drugs / interventions tested

Immunoglobulin of cured patients — full drug profile →
γ-Globulin — full drug profile →

Conditions studied

2019-nCoV — all drugs for 2019-nCoV →
Immunoglobulin of Cured Patients — all drugs for Immunoglobulin of Cured Patients →

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Who can join

18 and older, any sex, with 2019-nCoV or Immunoglobulin of Cured Patients. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The new coronavirus pneumonia is an acute infectious pneumonia. The pathogen is a previously unknown new coronavirus, namely 2019 new coronavirus (2019 novel coronavirus, 2019 nCoV). However, there is no specific anti-viral drug. It has been found that the specific antibodies against virus antigen are produced after these patients were cured, which could block the infection of 2019 nCoV on the host cells. At present, immunoadsorption is the most direct, rapid and effective method to separate immunoglobulin from the cured patients. Therefore, the study aims to prepare the immunoglobulin from 2019-ncov pneumonia cured patients, evaluate the efficacy and safety of the immunoglobulin in 2019-ncov pneumonia cured patients on the treatment of acute severe 2019-ncov pneumonia, and provide a new strategy for the treatment of 2019-ncov pneumonia.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

A serological assay to detect SARS-CoV-2 seroconversion in humans.
Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, et al · · 2020 · cited 1619× · PMID 32398876 · DOI 10.1038/s41591-020-0913-5
SARS-CoV-2 Vaccines: Status Report.
Amanat F, Krammer F. · · 2020 · cited 808× · PMID 32259480 · DOI 10.1016/j.immuni.2020.03.007
COVID-19: Transmission, prevention, and potential therapeutic opportunities.
Lotfi M, Hamblin MR, Rezaei N. · · 2020 · cited 447× · PMID 32474009 · DOI 10.1016/j.cca.2020.05.044
The Novel Coronavirus 2019 epidemic and kidneys.
Naicker S, Yang CW, Hwang SJ, Liu BC, et al · · 2020 · cited 383× · PMID 32204907 · DOI 10.1016/j.kint.2020.03.001
Ongoing Clinical Trials for the Management of the COVID-19 Pandemic.
Lythgoe MP, Middleton P. · · 2020 · cited 247× · PMID 32291112 · DOI 10.1016/j.tips.2020.03.006
Immune-mediated approaches against COVID-19.
Florindo HF, Kleiner R, Vaskovich-Koubi D, Acúrcio RC, et al · · 2020 · cited 219× · PMID 32661375 · DOI 10.1038/s41565-020-0732-3
COVID-19 and Cancer: a Comprehensive Review.
Gosain R, Abdou Y, Singh A, Rana N, et al · · 2020 · cited 187× · PMID 32385672 · DOI 10.1007/s11912-020-00934-7
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
Piechotta V, Chai KL, Valk SJ, Doree C, et al · · 2020 · cited 148× · PMID 32648959 · DOI 10.1002/14651858.cd013600.pub2

Verify or expand the search:

Other Union Hospital, Tongji Medical College, Huazhong University of Science and Technology trials

Trials by the same sponsor.

NCT07521124 — ABC Maintenance Therapy for AML · NA · not yet recruiting
NCT07497243 — X-ray Assisted Diagnostic System · not yet recruiting
NCT07520123 — Union-FAST: An Intelligent-Agent Intervention to Increase Antiviral Treatment Uptake in Diagnosed-but-Untreated Hepatiti · NA · not yet recruiting
NCT06970262 — FMT for Lung and Associated-organ Rescue Efficacy in ARDS Patients · NA · recruiting
NCT07509424 — Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Lo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04264858 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Last refreshed: 17 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04264858.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing